Bonus BioGroup
Bonus BioGroup initiated a preclinical study (“the Study”) of a unique drug product termed MesenCure, specially developed by the Company for the treatment of acute and life-threatening respiratory distress in coronavirus (COVID-19) and pneumonia patients.
Rankings by
National Ranking33rd
in Israel Regional Ranking50th
in Middle East Global Ranking1429th
worldwide